ADVM — ADVERUM BIOTECHNOLOGIES INC

Ownership history in UBS Group AG  ·  37 quarters on record

This page tracks every 13F SEC filing in which UBS Group AG reported a position in ADVERUM BIOTECHNOLOGIES INC (ADVM). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.01% (2020 Q2)
Avg. % of fund
0.0%
First filed
2016 Q2
Last filed
2025 Q3
Quarters held
37
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 5,585 -8,585 -60.6% 0.00% $25K —
2025 Q2 REDUCED 14,170 -43,378 -75.4% 0.00% $30K —
2025 Q1 ADDED 57,548 +9,952 +20.9% 0.00% $251K —
2024 Q4 ADDED 47,596 +35,188 +283.6% 0.00% $222K —
33 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)

Other funds also holding ADVM

As of 2025 Q3 — sorted by position size

BML Capital Management, LLC 3Y 12.68% Versant Venture Management, LLC 3Y 7Y 1.08% 5AM Venture Management, LLC 3Y 0.9% TCG Crossover Management, LLC 3Y 0.37% Frazier Life Sciences Management, L.P. 3Y 0.28% Pale Fire Capital SE 3Y 0.18% REGENERON PHARMACEUTICALS, INC. 0.12% Soleus Capital Management, L.P. 3Y 0.07% Quinn Opportunity Partners LLC 3Y 7Y 0.01% Waverly Advisors, LLC 3Y 7Y 0.01%
← Back to UBS Group AG Holdings